CL
COLGATE PALMOLIVE COEvidence as of 2026-09-29The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on CL
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · COLGATE PALMOLIVE CO
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing de…
Management team
- Mr. Dana Bolden · Chief Communications OfficerFind on LinkedIn
- Ms. Prabha Parameswaran · Group President of Growth & StrategyFind on LinkedIn
- Ms. Jennifer M. Daniels · Chief Legal Officer & SecretaryFind on LinkedIn
- Mr. Stanley J. Sutula III · Chief Financial OfficerFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.2 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The evidence balance is Mixed ( - 0.2 of a possible + 2 ; confidence high). Reported revenue for fiscal Q2 2026 (fiscal quarter ended 2026-06-30) was 5,361,000,000, up from 5,324,000,000 in fiscal Q1 2026 (fiscal quarter ended 2026-03-31) and from 5,110,000,000 in fiscal Q2 2025 (fiscal quarter ended 2025-06-30). Gross profit rose to 3,296,000,000 in fiscal Q2 2026 (margin ~ 61.5%), operating income was 1,016,000,000, and net income was 693,000,000; diluted shares fell to 801,800,000 and point-in-time shares to 797,172,829 as of 2026-06-30, with repurchase activity shown (PaymentsForRepurchaseOfCommonStock 306,000,000 in fiscal Q1 2026).
Balance-sheet and market metrics coexist: long-term debt noncurrent moved to 7,823,000,000 as of 2026-06-30 while cash and equivalents were 1,370,000,000; trailing metrics show P/FCF (ttm) 31.36, EV/EBITDA (ttm) 15.92, P/E (ttm) 24.86, and an implied free-cash-flow growth rate the model ties to 20.31% per year. Filings disclose a Board-approved three-year Strategic Growth and Productivity Program and expanded risk language on eCommerce, AI, inflationary pressures and Venezuela, while news items report a potential brand-sale process and emphasize the company’s long dividend streak. Insider Form 4 activity in September 2026 shows multiple open-market purchases by the CEO and other officers.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenue was 5,361,000,000 for fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), up from 5,324,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and up from 5,110,000,000 in fiscal Q2 2025 (2025-04-01 to 2025-06-30, 3mo).
XBRL companyfacts · 0000021665-26-000042Gross profit was 3,296,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo) versus 3,226,000,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and 3,069,000,000 in fiscal Q2 2025 (2025-04-01 to 2025-06-30, 3mo); expressed as margins, gross profit/ revenue is about 61.5% in fiscal Q2 2026, 60.6% in fiscal Q1 2026, and 60.1% in fiscal Q2 2025 (calculated from those facts).
XBRL companyfacts · 0000021665-26-000042Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
The company's Annual Report on Form 10-K filed 23 February 2026 discloses a Board-approved three-year "Strategic Growth and Productivity Program" (approved July 31, 2025) intended to align organizational structure, optimize the global supply chain and simplify the organization, and notes that successful implementation "may present significant organizational challenges."
Item 1A risk-factor diff · 0000021665-26-000006 vs 0000021665-25-000008The 10-K filed 23 February 2026 adds risk language noting that local operating results from the company's Venezuela operations have not been included in consolidated financial statements since December 31, 2015, while also stating that uncertainties in Venezuela "could have ramifications" for the company's business in Venezuela and the broader Latin American region.
Item 1A risk-factor diff · 0000021665-26-000006 vs 0000021665-25-000008Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
13F-reported institutional holdings total $58.54B as of 2026-06-30 and list BlackRock, Inc. ($6.41B), VANGUARD CAPITAL MANAGEMENT LLC ($4.79B), and STATE STREET CORP ($4.31B) among the top holders; the 13F note states filings carry a 45-day reporting lag.
13F holdings · 2027 filers · as of 2026-06-30As of 2026-09-23 (VTI) and 2026-09-22 (IVV), CL appears as a constituent with fund weights of 0.14% in VTI and 0.11% in IVV.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Several headlines report that Colgate-Palmolive is exploring the potential sale of mass-market personal care brands (Softsoap, Irish Spring, Speed Stick) and is working with Goldman Sachs on the process.
News · finance.yahoo.com · 2026-09-28Syndicated coverage repeating the brand-sale theme appears in more than one outlet, with a similar story running on InsiderMonkey.
News · insidermonkey.com · 2026-09-28Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No 10b5-1 or trading-plan box is indicated in the filings for the insider transactions listed; each transaction record shows trading_plan: null.
Form 4 · Fishbone Betsy (CLO and Secretary) · $41k code F · 2026-09-13Wallace Noel R. (Chairman, President & CEO) executed three open-market purchases: $353k for 4,071 shares on 2026-09-11; $305k for 3,516 shares on 2026-09-12; and $425k for 4,892 shares on 2026-09-13 (each filed separately).
Form 4 · Wallace Noel R. (Chairman, President & CEO) · $425k code F · 2026-09-13Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The market-priced implied free cash flow growth rate that today's price would justify, under the model's stated discount and terminal assumptions, is 20.31% per year.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-free-cash-flow (P/FCF, trailing twelve months) is 31.36, based on fcf_ttm = $2,212,000,000 and the reported market price.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several contemporaneous data points together support a favorable read: sequential and year-over-year revenue and gross-profit expansion (fundamentals-0, fundamentals-1) with improving gross margins indicate operating leverage at the top line, while ongoing share repurchases have meaningfully reduced diluted share count (fundamentals-4) which accentuates per-share metrics. Insider open-market purchases by multiple senior executives, including the CEO and CFO (insider-1, insider-2, insider-3, insider-4), and sizable institutional ownership (ownership-0) add corroborating signals of internal and market investor conviction. Active portfolio moves reported in the press — selling mass-market personal care brands with advisory engagement (news-0, news-1) — are consistent with management taking steps to optimize the business mix, complementing the firm-level strategic program disclosed in filings (filings-0) rather than undermining it. While headline valuation metrics note a high implied growth rate and elevated P/FCF (valuation-0, valuation-1), the company’s sizable trailing free-cash-flow generation and market-scale cash flow (valuation-4) provide evident capacity to fund buybacks, investment, or strategic actions noted above.
Chair's verdict, claim by claim
Fragility · computed, not argued
diversified0.26
31 surviving claims rest on 19 distinct sources; the heaviest analyst carries 23% of them, and 98% of what the desk raised survived the debate.
The evidence set is moderately robust: 31 surviving claims draw on 19 distinct sources, which gives some cross-checking but still leaves room for single-source impacts. The fact one analyst contributed nearly a quarter of claims and 98% of proposed points survived debate suggests low internal pushback — useful for signal continuity but also a possible confirmation-concentration risk that reduces the weight you should place on any single disputed item.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
11 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.5 to the score
12 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−0.8 to the score
3 holdings records· 2 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.3 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
8 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot+1.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on CL Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.